Previous close | 0.0260 |
Open | 0.0290 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 1800 |
Day's range | 0.0240 - 0.0290 |
52-week range | 0.0120 - 4.3750 |
Volume | |
Avg. volume | 832,163 |
Market cap | 258,597 |
Beta (5Y monthly) | -1.20 |
PE ratio (TTM) | 0.00 |
EPS (TTM) | 38.9700 |
Earnings date | 26 Apr 2024 - 30 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:
Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program.
Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more